News

Join the CCS for the third and final installment of the Amyloid Education Series 2.0 in the upcoming webinar, ‘Cases and Clinical Conundrums in Amyloidosis…

The WashU Medicine Amyloid Center of Excellence has been selected as one of just 10 centers nationwide to participate in the American Heart Association’s ATTR-CM…

CAMBRIDGE, Mass. - Alnylam Pharmaceuticals (NASDAQ:ALNY) announced Tuesday partnerships with Viz.ai and the American Heart Association aimed at improving early…

Alnylam Pharmaceuticals highlighted the early commercial success of AMVUTTRA (vutrisiran) for ATTR cardiomyopathy during a recent webinar. The company reported a…

New AI Care Pathway combines AI echocardiography analysis with coordinated, guideline-based next steps for cardiology and heart failure teamsSAN FRANCISCO, CA –…

AbstractBackgroundLight-chain amyloidosis (AL) is a rare plasma cell disorder characterized by extracellular deposition of misfolded light chains in multiple organs…

PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on…

1 research study open to eligible peoplehATTR is a genetic condition where faulty transthyretin protein builds up as amyloid. UCSF is carrying out an observational…

AL amyloidosis is when abnormal proteins called light chains collect in organs. UCSF is studying a drug for people with relapsed or refractory multiple myeloma or…

a study on AL AmyloidosisAmyloidosisOpen-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120…